Abstract
Chromogranin-A is considered a sensitive immunohistochemical tissue marker in neuroendocrine prostatic carcinoma. We report that the plasma chromogranin-A level was elevated in 48% of 25 patients with stage D2 prostate cancer, and suggest that this marker can be used to monitor the clinical course of these patients.
Publication types
-
Case Reports
-
Comparative Study
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Aged
-
Aged, 80 and over
-
Biomarkers / blood
-
Carcinoma / blood*
-
Chromogranin A
-
Chromogranins / blood*
-
Humans
-
Male
-
Middle Aged
-
Prostatic Neoplasms / blood*
-
Radioimmunoassay
Substances
-
Biomarkers
-
CHGA protein, human
-
Chromogranin A
-
Chromogranins